Premium
Synthesis and in vitro Characterization of Semitelechelic Poly[ N ‐(2‐hydroxypropyl)methacrylamide]–Trastuzumab Conjugates Targeted to Breast Cancer
Author(s) -
Lee Jun H.,
Sabnis Gauri,
Nan Anjan
Publication year - 2012
Publication title -
macromolecular bioscience
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 105
eISSN - 1616-5195
pISSN - 1616-5187
DOI - 10.1002/mabi.201100152
Subject(s) - trastuzumab , conjugate , methacrylamide , chemistry , cancer cell , monoclonal antibody , antibody drug conjugate , in vitro , breast cancer , cancer research , cancer , pharmacology , antibody , biochemistry , medicine , immunology , mathematical analysis , acrylamide , mathematics , organic chemistry , copolymer , polymer
Trastuzumab (TRZ) is a humanized monoclonal antibody that targets the extracellular domain of the human epidermal growth factor receptor type 2 (Her2). Semitelechelic (ST) poly[ N ‐(2‐hydroxypropyl)methacrylamide]–TRZ conjugates are successfully synthesized and evaluated as a potential drug delivery system that actively targets Her2‐overexpressing cancer cells. The ST backbone shows favorable characteristics when conjugated to TRZ. The conjugate exhibits comparable and prolonged anticancer activity when compared to free TRZ in Her2 overexpressing breast cancer cell lines.